Literature DB >> 1735956

Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins).

G T Bramblett1, J Q Trojanowski, V M Lee.   

Abstract

Paired helical filaments, the dominant filamentous components of Alzheimer's disease (AD), neurofibrillary tangles (NFT), neuropil threads, and the dystrophic neurites associated with amyloid rich senile plaques, are composed of abnormally phosphorylated derivatives of tau known as A68 proteins. Indeed the inappropriate phosphorylation of Ser396, which is adjacent to the microtuble binding domain in tau, may contribute to the transformation of tau into A68 and prevent A68 from efficiently binding to microtubules. The reduced levels of normal soluble tau proteins in AD brains may be the consequence of a multi-step process whereby normal tau is converted into A68 and sequestered in paired helical filaments. To elucidate the events involved in this process, we compared the relative levels of binding-competent (BC) and binding-incompetent (BI) tau with the level of A68 in six different regions (hippocampus, fornix, frontal grey and white matter, and cerebellar grey and white matter) of fresh AD and control brains. When the AD brains were compared as a group with neurologically normal and diseased non-AD controls, quantitative immunoblot analysis demonstrated a selective reduction of BC tau in regions of the AD brains with abundant neurofibrillary lesions (NFTs, neuropil threads, and senile plaque neurites) and in their associated white matter areas. The level of BI tau was similar in both AD and control brains. In contrast, A68 was present only in the AD brains, but it was confined to those brain regions with abundant NFTs, neuropil threads, and senile plaques. We view the reductions in BC tau in fornix and frontal white matter to be a consequence of the reductions in their associated grey matter regions i.e., hippocampus and frontal grey matter. Although there is no strict relationship between the reduction of BC tau and the level of A68 within an individual brain, the comparison of the AD group with the control group suggests that the grey matter of the affected regions may be the site for the conversion of BC tau into A68. Further, this process may occur rapidly or via pathways that do not involve BI tau since the levels of BI tau were similar in AD and control brains. Although the complete sequence of events leading to the transformation of tau into A68 and paired helical filaments remains to be elucidated, our data provide compelling evidence that A68 proteins are generated from tau-proteins in selected regions of the AD brain where neurofibrillary lesions comprised of paired helical filaments accumulate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735956

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  28 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons.

Authors:  S E Merrick; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it.

Authors:  John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

4.  The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.

Authors:  Bin Zhang; Jenna Carroll; John Q Trojanowski; Yuemang Yao; Michiyo Iba; Justin S Potuzak; Anne-Marie L Hogan; Sharon X Xie; Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; Kurt R Brunden
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

Review 5.  Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

Authors:  Kurt R Brunden; Carlo Ballatore; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

6.  Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays.

Authors:  Alex Crowe; Mark J Henderson; Johnathon Anderson; Steven A Titus; Alexey Zakharov; Anton Simeonov; Arjan Buist; Charlotte Delay; Diederik Moechars; John Q Trojanowski; Virginia M-Y Lee; Kurt R Brunden
Journal:  J Biol Chem       Date:  2020-02-07       Impact factor: 5.157

Review 7.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 8.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

9.  Alzheimer disease A68 proteins injected into rat brain induce codeposits of beta-amyloid, ubiquitin, and alpha 1-antichymotrypsin.

Authors:  R W Shin; G T Bramblett; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins.

Authors:  V Buée-Scherrer; L Buée; P R Hof; B Leveugle; C Gilles; A J Loerzel; D P Perl; A Delacourte
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.